• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

0
  • by alexperjescuadmin
  • in Oncology
  • — 14 Dec, 2007
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
AudioMedica News
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-390"/>
Stephen Jones
Stephen Jones

STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071213_stephen_jones.mp3]

Share

Tags: breast cancer survivalbreast-cancercyclophosphamidedocetaxeldoxorubiciniphoneOncologyoncology researchstephen jonessurvival advantagesurvival benefittaxanethorneus oncology

You may also like...

  • Philippe Autier Colorectal cancer screening: survey of 11 European countries finds big mortality benefit 6 Nov, 2013
  • Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer 2 Nov, 2007
  • Michael Gnant MD, a Professor and Director of the Medical University of Vienna Targeting Bone Microenvironment in Breast Cancer 27 Mar, 2015
  • Rosalind Perrin MD ‘Rescanning’ Optimizes Pencil Beam Proton Delivery to Moving Lung Tumor 12 May, 2015

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
  • Next story AACR In New Partnership For San Antonio Breast Cancer Symposium
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Brachytherapy “Excellent” After Breast…
    • PD-L1 Immunotherapy Delayed Triple Negative Breast…
  • Home
  • Oncology
  • Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.